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Diabetes mellitus (DM) is associated with macrovascular and microvascular complications. Platelets have a “key role” in
atherogenesis and its thrombotic complications in subjects with DM. Moreover, the concomitant presence of multiple “classical”
cardiovascular risk factors in diabetic subjects contributes to enhanced atherothrombotic risk. Antiplatelet agents are eﬀective
in primary and secondary prevention of arterial thrombosis (cardiovascular events, ischaemic stroke, and peripheral arterial
occlusive disease). The role of chronic administration of antiplatelet drugs in primary prevention of arterial vascular events is
known to be less clear than in secondary prevention, and, also in diabetic patients, the decision to give primary prophylaxis
should be taken on an individual-patient basis, after a careful evaluation of the balance between the expected beneﬁts and the risk
of major bleedings. Although, currently, treatment has proven useful in reducing vascular events, diabetic patients continue to
have a higher risk of adverse cardiovascular events compared with those in nondiabetic patients. This paper reviews the role
of currently available antiplatelet drugs in primary and secondary prevention of vascular events in diabetic patients and the
limitations of these drugs, and it discusses the role of novel and more potent antiplatelets and of new agents currently under
clinical development.
1.Introduction
Diabetes mellitus (DM) is associated with macrovascular
and microvascular complications (coronary artery disease,
ischemicstroke,peripheralarterialdisease,nephropathy,and
retinopathy) [1, 2].
Platelets have a “key role” in atherogenesis and its
thrombotic complications in subjects with DM [3], and the
concomitant presence of multiple “classical” cardiovascular
risk factors (arterial hypertension, cigarette smoking, and
hyperlipidemia) in diabetic subjects contributes to enhanced
atherothrombotic risk.
Platelets from subjects with DM, particularly from those
with type 2 diabetes, exhibit increased reactivity. Factors
that may contribute to this greater platelet reactivity are not
completely elucidated and include metabolic abnormalities
as hyperglycemia, hyperlipidemia, insulin resistance, and
conditions as oxidative stress, inﬂammation, and endothelial
dysfunction [3].
A close relationship between poor glycemic control and
increased platelet activity (estimated by measuring mean
platelet volume—MPV—as part of whole blood count) in
patients with type 2 DM has been suggested [4]. MPV
is considered a marker of platelet function and activa-
tion: larger platelets are more reactive and aggregable.
They contain denser granules, secrete more serotonin and
β-thromboglobulin, produce more thromboxane A2 and
have more adhesion molecules (like P-selectin and platelet
glycoprotein—GP—IIbIIIa), than smaller platelets. It has
been shown that MPV is signiﬁcantly higher in diabetic
populations [5]. It is also increased in hypercholesterolemia,
metabolic syndrome, acute myocardial infarction, acute
ischemic stroke, preeclampsia, and renal artery stenosis
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Available antiplatelet agents, such as cyclooxygenase-1
(COX-1) inhibitors (aspirin), ADP P2Y12 receptor antago-
nists, and GP IIb/IIIa receptor inhibitors, are eﬀective and
save in the treatment and prevention of thrombotic events,
these drugs interfere with the platelet activation process,
including adhesion, release, and aggregation.
However, although the currently available treatments
haveproventobeusefulinreducingischemicevents,diabetic
patientscontinuetohaveahigherriskofadverseeventscom-
pared with those in non-diabetic patients. The role of novel
and more potent antiplatelet strategies, currently under
clinical development, seems attractive in diabetic patients.
2.AntiplateletDrugsinDiabeticPatients
Cardiovascular (CV) diseases are the leading cause of mor-
bidity and mortality in diabetic patients. The ﬁrst evidence
of an increased platelet aggregation in diabetics dates back
to 1965 [6]. Large clinical trials have shown that antiplatelet
agents are eﬀective in the prevention of recurrent cardio-
vascular events in diabetes. The most prescribed agents are




for use in primary prevention, and the beneﬁt of aspirin
among diabetic patients with no previous cardiovascular
events is still controversial [10]. In 2007 the American
Diabetic Association (ADA) and the American Heart Asso-
ciation (AHA) recommended low doses of aspirin (75–
162mg/day) in primary prevention in diabetics at high
cardiovascular risk [11, 12] (i.e., those >40 years of age or
with additional risk factors: family history of CV disease,
arterial hypertension, cigarette smoking, dyslipidemia, or
albuminuria) [13].
In contrast, in the European guidelines aspirin is recom-
mended in primary prevention of ischemic stroke [14].
The results of two recent randomized controlled trials in
patients with diabetes raised questions about the eﬃcacy of
aspirininprimaryprevention[15,16].TheJapanesePrimary
Prevention of Atherosclerosis with Aspirin for Diabetes
(JPAD) trial was the ﬁrst prospective trial to evaluate the
use of aspirin (81 or 100mg) in the primary prevention of
ischemic events in diabetic type 2 patients (n = 2,539),
aged 30–85 years, in Japan [15]. In this trial aspirin did not
reduce the risk of events in diabetic patients, unless they
are aged 65 years and above (P = .047 for patients >65
years) [15]. However, aspirin was well tolerated, and there
was no signiﬁcant increase in hemorrhagic complications
and hemorrhagic strokes [15].
The Prevention of Progression of Arterial Disease and
Diabetes (POPADAD) randomized trial failed to show any
beneﬁt of aspirin (100mg) or antioxidant substances in
primary prevention of vascular events in diabetic patients
(n = 1,276) aged >40 years with an ankle-brachial index
≤0.99, but no symptomatic CV disease. However, this
should not be considered a primary prevention trial because
the subjects studied had some degree of peripheral arterial
disease (PAD) [16].
Moreover, a clear beneﬁt of aspirin (versus placebo) in
primary prevention of major cardiovascular events or mor-
tality in diabetes was unconﬁrmed in a meta-analysis [17].
Finally, the decision to give aspirin must be taken on
an individual patient basis, after a careful evaluation of the
balance between the expected beneﬁts and the risk of major
bleedings [18–20].
Two clinical trials are currently underway, which will
provide insights to the usefulness of aspirin in primary
prevention in diabetes: A Study of Cardiovascular Events in
Diabetes(ASCEND;aspirin75mgversusomega-3fattyacids
1g), and Aspirin and Simvastatin Combination for Cardio-
vascular Events Prevention Trial in Diabetes (ACCEPT-D;
simvastatin 20–40mg versus aspirin 100mg, or simvastatin
alone).
4.Secondary Prevention
In secondary prevention ADA recommends low-dose aspirin
(75–162mg/d) in diabetic patients aﬀected by vascular
events [21]. This position is supported by the results of
two large meta-analyses by the Antithrombotic Trialists’
Collaboration (ATC), which showed aspirin to be protective
in patients at high cardiovascular risk, including those with
diabetes [22, 23].
A valid option for patients with aspirin intolerance is
represented by ticlopidine and clopidogrel, thienopyridines
which aﬀect the adenosine diphosphate (ADP) pathway, by
blocking the platelet ADP receptor P2Y12 [24].
Clopidogrel has a more favourable safety proﬁle com-
pared with ticlopidine [23]. Bhatt et al. retrospectively
analyzed a subgroup of diabetic patients (20% of the study
population) in the Clopidogrel versus Aspirin in Patients at
Risk of Ischemic Events (CAPRIE) study. Clopidogrel was
signiﬁcantly more eﬀective than aspirin in reducing the risk
of ischaemic events in diabetic patients with a history of
atherothrombosis [25, 26]. American Diabetes Association
guidelines currently recommend the use of clopidogrel in
very high-risk diabetic patients, or as an alternative strategy
in aspirin-intolerant patients [21].
TheClopidogrelinUnstableAnginatoPreventRecurrent
Events(CURE)study(aspirinplusclopidogrel,versusaspirin
alone, in patients with unstable angina or non-ST elevation
myocardial infarction) conﬁrmed the eﬃcacy of the drug
in acute coronary syndromes (ACS), with similar results
in diabetic patients. Moreover, the study showed that the
event rate was much higher in the diabetic than in non-
diabetic group, despite the adjunctive use of clopidogrel
[27].
Numerous trials have shown clinical beneﬁts for the Gp
IIb/IIIa antagonists (abciximab, eptiﬁbatide, and tiroﬁban).
These drugs signiﬁcantly reduce the mortality after percu-
taneous coronary intervention (PCI) in all subgroups of
patients considered, including diabetics [28]. These results
support the use of Gp IIb/IIIa receptor antagonists in
high risk ACS patients, in particular those with diabetes
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5. Limitationsof CurrentlyAvailable
AntiplateletDrugsandFutureDirections
There is a reduced clinical eﬃcacy (“aspirin resistance”) of
aspirinindiabeticcomparedwithanon-diabeticpopulation.
Hyperglycemia may be one of the mechanisms involved in
this phenomenon. Increased glycation of platelets and coag-
ulation factors may interfere with acetylation by aspirin [29–
35]. This may explain the greater eﬀectiveness of clopidogrel
in preventing vascular events in diabetes, as compared with
low-dose aspirin [26].
On the other hand, “clopidogrel resistance”i saw e l l -
described phenomenon in diabetic as well as in non-diabetic
patients, with severe clinical consequences (e.g., throm-
boembolic complications after coronary stent implantation)
[36, 37].
Insulin, which interacts with its own receptor on platelet
surface, reduces platelet reactivity, by suppressing cAMP and
by inhibiting P2Y12 signalling. Platelets of diabetic patients
are aﬀected by the insulin resistance, which results in an
upregulation of the P2Y12 pathway and in an increased
platelet reactivity [38].
(1) Low and high doses of aspirin demonstrate simi-
lar reduction in cardiovascular endpoints [22, 23].
Whether the use of higher-doses aspirin in diabetes
reduces cardiovascular morbidity is still uncertain
[39, 40], but this approach is actually unjustiﬁable
and even unsafe in diabetes, for the increased
hemorrhagic and gastrointestinal risk. The available
evidence does not consider aspirin doses >100mg
daily as either eﬀective or safe [41].
(2) Moreover, aspirin given once daily might be insuf-
ﬁcient for patients with increased platelet turnover,
as are diabetic patients. “Multiple daily doses,” rather
than an increase in a once-daily dose, might be more
beneﬁcial in these patients [42–44], as we ﬁrstly
showed about 30 years ago [45].
(3) The association between aspirin and other
antiplatelet drugs in some categories of diabetic
patients at high thrombotic risk may be considered.
In high-risk categories (i.e., ACS) the overall beneﬁts
outweigh the increased bleeding risk [46].
Several studies have shown the beneﬁt of triple
therapy with aspirin, clopidogrel, and cilostazol
(a phosphodiesterase III inhibitor), particularly in
diabetic patients treated with bare-metal or drug-
eluting stents. However, cilostazol therapy has side
eﬀects (migraine, palpitations, and gastrointestinal
problems) [47].
(4) Several studies have focused on how to overcome
“clopidogrel resistance” by increasing the dose. In the
OptimizingAntiplateletTherapyinDiabetesMellitus
(OPTIMUS) study, the use of clopidogrel 150mg/d,
chronically, resulted in greater platelet inhibition
than clopidogrel 75mg in type 2 diabetes mellitus
[48, 49].
(5) New agents are under advanced clinical investigation.
These include prasugrel and ticagrelor, which
are administered orally, and cangrelor that is
administered intravenously, and elinogrel that can be
administered in oral and endovenous route. Between
orally administered drugs, prasugrel is a third-
generation thienopyridine that, like clopidogrel,
exerts its antiplatelet eﬀect by P2Y12 receptor
blockade. However, prasugrel has a more favourable
pharmacokinetic proﬁle because it is more eﬃciently
transformed in its active metabolite. In the TRITON-
TIMI 38 trial, comparing prasugrel (a 60mg loading
dose and a 10mg daily maintenance dose) with
clopidogrel (a 300mg loading dose and a 75mg daily
mainteinance dose) in 13,608 patients who under-
went percutaneous coronary revascularization, pra-
sugrel signiﬁcantly reduced the composite primary
endpoint of death, nonfatal myocardial infarction
and nonfatal stroke (9.9% versus 12.1%, HR 0.81;
95% CI 0.73–0.90; P<. 001). This clinical beneﬁt was
greaterindiabeticpatientsthanamongpatientswith-
out diabetes (12.2% versus 17%; HR 0.70, P<. 001)
[50].
Another alternative to aspirin to prevent cardiovascular
events in diabetes is considered picotamide (thromboxane
A2 synthase and thromboxane A2 receptors inhibitor).
The Drug Evaluation in Atherosclerotic Vascular Disease
in Diabetics (DAVID) study is the ﬁrst trial showing a
signiﬁcant reduction of overall mortality by picotamide
versus aspirin in patients at high cardiovascular risk, and
in diabetics with peripheral artery disease [51]. These
data have to be more extensively evaluated in clinical
trial.
6. Conclusions
(1) Recent ﬁndings do not support the use of aspirin
in primary prevention of cardiovascular events in
diabetics, at diﬀerence with secondary prevention.
While we await the results of two undergoing pri-
mary prevention trials (ASCEND and ACCEPT-D),
patients with type 2 DM at high risk of cardiovas-
cular events should be considered for low-doses of
aspirin (75–162mg/day) in primary prevention. A
decision should be taken on an individual patient
basis.
(2) The optimal control of hyperglicemia and other risk
factors (arterial hypertension, hyperlipidemia, and
cigarette smoking) is necessary to decrease platelet
reactivity and to enhance the eﬃcacy of antiplatelet
drugs.
(3) Recurrent cardiovascular events in diabetic patients,
despite antiplatelet therapy, underscore the need of
individualized antiplatelet regimens. More speciﬁc
antiplatelet strategies, as more potent drugs or an
association between antiplatelet drugs are warranted
in diabetic patients.4 International Journal of Vascular Medicine
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